Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats

被引:66
|
作者
Sancho, V
Trigo, MV
González, N
Valverde, I
Malaisse, WJ
Villanueva-Peñacarrillo, ML
机构
[1] Fdn Jimenez Diaz, Dept Metab Nutr & Hormones, E-28040 Madrid, Spain
[2] Free Univ Brussels, Lab Expt Hormonol, Brussels, Belgium
关键词
D O I
10.1677/jme.1.01747
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several kinases have been implicated in the metabolic response of human and rat myocytes to glucagon-like peptide-1 (GLP-1), exendin-4 (Ex-4) and exendin-9 (Ex-9). We have investigated, in isolated rat adipocytes, the changes caused by GLP-1, Ex-4 and Ex-9 compared with those provoked by insulin or glucagon, upon the activity of phosphatidylinositol-3-kinase (PI3K), protein kinase B (PKB), p42/44 MAP kinases (MAPKs) and p70s6 kinase (p70s6k), and the participation of these kinases and protein kinase C (PKC) in their action upon 2-deoxy-(D)-glucose uptake, lipolysis and lipogenesis. The study was conducted in normal rats, and extended to a streptozotocin-induced type-2 diabetic model (STZ-rats). The participation of distinct kinases was estimated by using potential kinase inhibitors, including wortmannin, PD98059, rapamycin, H-7 and RO31-8220. In normal rat adipocytes, GLP-1 and both exendins share with insulin an increasing action upon the activity of all kinases studied (except PKB), PI3K, p44 and p42 MAPKs and possibly PKC, all being required for their stimulating effect upon glucose uptake. Ex-4 and Ex-9, like GLP-1 and insulin, have lipogenic action, while only Ex-4 shares with GLP-1 its lipolytic effect which is antagonized by Ex-9. MAP kinases and PKC seem to have an essential role in the GLP-11 and Ex-4 lipolytic action, as does PI3K in that of Ex-4. An increase in PI3K and MAPKs activity for the lipogenic effect of Ex-4, Ex-9 and GLP-1 are required, and in the case of Ex-4 and Ex-9, a stimulation of p70s6k activity is also needed. In cells from STZ-rats the magnitude of the above parameters was, in general, comparable to that in normal animals, with some exceptions: basal PI3K activity and lipogenesis were higher, GLP-1, Ex-4 and Ex-9 failed to modify basal lipogenesis but increased PKB activity, insulin failed to affect the activity of MAPKs and the insulin-induced glucose uptake was impaired. The impaired insulin effects upon some of the variables in the STZ-rat, distinct from those of GLP-1 and exendins, adds knowledge to the mechanism of the beneficial action of GLP-1 and Ex-4 in diabetic states.
引用
收藏
页码:27 / 38
页数:12
相关论文
共 50 条
  • [21] Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs
    Nishizawa, M
    Moore, MC
    Shiota, M
    Gustavson, SM
    Snead, WL
    Neal, DW
    Cherrington, AD
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2003, 284 (05): : E1027 - E1036
  • [22] EFFECT OF GLUCAGON-LIKE PEPTIDE-1 ON GLUCOSE-TURNOVER IN NORMAL MAN
    HOLST, JJ
    HVIDBERG, A
    NIELSEN, MT
    HILSTED, J
    ORSKOV, C
    DIGESTION, 1993, 54 (06) : 383 - 384
  • [23] Glucagon-Like Peptide-1 Increases Brain fMRI Activity in Rats
    Min, David K.
    Tuor, Ursula I.
    Chelikani, Prasanth K.
    OBESITY, 2011, 19 : S171 - S171
  • [24] Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes
    Luque, MA
    González, N
    Márquez, L
    Acitores, A
    Redondo, A
    Morales, M
    Valverde, I
    Villanueva-Peñacarrillo, ML
    JOURNAL OF ENDOCRINOLOGY, 2002, 173 (03) : 465 - 473
  • [25] Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase a in hepatocytes from normal and diabetic rats
    López-Delgado, MI
    Morales, M
    Villanueva-Peñacarrillo, ML
    Malaisse, WJ
    Valverde, I
    ENDOCRINOLOGY, 1998, 139 (06) : 2811 - 2817
  • [26] DRY POWDER INHALATION OF GLUCAGON-LIKE PEPTIDE-1 FOR MANAGEMENT OF TYPE-2 DIABETES MELLITUS
    Pandya, Sanketkumar
    Kumar, Durgesh
    Gupta, Swati
    Mitra, Kalyan
    Gaikwad, Anil N.
    Misra, Amit
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2019, 32 (02) : A19 - A19
  • [27] Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus
    Cuthbertson, Joy
    Patterson, Steven
    O'Harte, Finbarr P.
    Bell, Patrick M.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2011, 60 (01): : 52 - 56
  • [28] The Differential Effect of Glucagon-Like Peptide-1 Receptor Blockade on Glucose Metabolism in People With and Without Type 2 Diabetes
    Welch, Andrew A.
    Farahani, Rahele A.
    Zeini, Maya
    Egan, Aoife M.
    Laurenti, Marcello C.
    Cobelli, Claudio
    Man, Chiara Dalla
    Vella, Adrian
    DIABETES, 2023, 72
  • [29] Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents
    Oguma, Takahiro
    Nakayama, Keiko
    Kuriyama, Chiaki
    Matsushita, Yasuaki
    Yoshida, Kumiko
    Hikida, Kumiko
    Obokata, Naoyuki
    Tsuda-Tsukimoto, Minoru
    Saito, Akira
    Arakawa, Kenji
    Ueta, Kiichiro
    Shiotani, Masaharu
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2015, 354 (03): : 279 - 289
  • [30] Effects of Glucagon-like Peptide-1 in Diabetic Rat Small Resistance Arteries
    Bayram, Zeliha
    Nacitarhan, Cahit
    Ozdem, Sadi S.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2014, 64 (03) : 277 - 284